新福菌素联合卡铂依托泊苷治疗老年非小细胞肺癌疗效观察临床医学.docVIP

新福菌素联合卡铂依托泊苷治疗老年非小细胞肺癌疗效观察临床医学 目录 TOC \o 1-9 \h \z \u 目录 1 正文 1 文1：新福菌素联合卡铂依托泊苷治疗老年非小细胞肺癌疗效观察临床医学 1 1 资料和方法 3 2 结果 4 3 讨论 4 文2：吉西他滨联合卡铂治疗老年非小细胞肺癌耐受性及疗效分析临床医学 5 1 材料与方法 5 2 结 果 7 3 讨 论 8 参考文摘引言： 8 原创性声明（模板） 9 文章致谢（模板） 10 正文 新福菌素联合卡铂依托泊苷治疗老年非小细胞肺癌疗效观察临床医学 文1：新福菌素联合卡铂依托泊苷治疗老年非小细胞肺癌疗效观察临床医学 【ABSTRACT】 Objective:To investigate the curative effects and sideeffect of domestic drugSinoactionomycin in treating elderly nomall cell lung cancer (CLC).Methods: 81 cases with elderly CLC were divided into two groups randomly,43 cases in the treatment group were administrated with Sinoactionomycin 6g/kg (1~4 day) combining card platinum (CBP) 300mg/m2 (1st day), glucoside (VP16) 100 mg (1~4 or 5days) cases in the control group were only treated with CBP and vp16 and the dosage were same with that of treatment ~28 days were taken as a treatment cycle and the curative effects were studied after 2~3 relievable and survival periods were investigated as : The effectiveness for treatment troup is 5349%, effectiveness for control group is 3158%, the difference has the significance (P005); The central relievable period is 6 and 45 months respectively, and the central survival period is 9 and 7 months respectively,on year survival rate respectively is 3953% (17,/43) and 2632% (10,/38). Conclusion: Sinoactionomycin combining CBP,and VP16 has good clinical curative effect in treating elderly CLC and has the good clinical practice value. 【KEY WORDS】 Elderly; Nomall cell lung cancer; Chemotherapy; Sinoactionomycin; Card platinum; VP16 肺癌一直是男女癌症患者死亡的主要因素[1]。由于非小细胞肺癌（CLC）占原发性肺癌的75%~80%，50%以上的CLC患者确诊时年龄超过65岁，1/3 的CLC在确诊时年龄超过70岁[2]。另外，老年人脏器储备能力降低，尤其合并慢性心肺疾病者，因此绝大多数老年CLC患者在确诊时失去手术机会，治疗主要采用以化疗为主的综合治疗，虽然异长春花碱、紫杉醇等新的抗癌药物的使用取得了良好的临床效果，但铂类和依托泊苷（VP16）联用仍是治疗CLC的基本化疗方案。新福菌素加用卡铂（CBP）和VP16治疗CLC国内报道较少，为了进一步观察其临床疗效和毒性反应，我们对我院81例老年CLC患者的化疗的近期疗效进行了观察，现报告如下。 1 资料和方法 11 一般资料所选81例老年患者均系经病理组织学或细胞学证实的CLC，按1997年国际抗癌联盟（UICC）制定的TNM分期标准，Ⅱ期14例，Ⅲa期21例，Ⅲb、Ⅳ期46例；预计生存期均在3个月以上，并发慢阻肺者21例，冠